INSUBCONTINENT EXCLUSIVE:
business models.Over the past several years, a long list of innovative startups and salivating venture investors have pinned their focus on
repairing the healthcare industry, but its digital transformation still appears to be in the very early innings
After a record-setting 2018, however, digital health investing continued to reach meteoric heights in 2019.Mammoth pools of capital have
flooded into various sub-verticals and business models, backing collections of new B2B and B2C companies focused on optimizing healthcare
workflows, improving healthcare access and offering lower-cost distribution models
Over the past two years, digital health startups have raised well over $10 billion in funding across nearly 1,000 deals, according to data
from Pitchbook and Crunchbase.As we close out another strong year for innovation and venture investing in the sector, we asked nine leading
sector:Participants discuss trends in digital therapeutics, telehealth, mental health and the latest in biotech and medical devices, while
also diving into startups improving medical practitioner efficiency, evaluating the evolving regulatory environment and debating valuations
a long history of investing in iconic health companies, we believe it is still the early innings of digital health as a category today.When
I evaluate new opportunities in the space, I often start by thinking through how the company will move the needle on cost, quality, and
For example, Viz.ai is using artificial intelligence to detect and alert stroke teams to suspected large vessel occlusion strokes, enabling
patients to get treatment faster
type of tech-enabled care outside of the hospital setting
Modern Health is a mental health benefits platform that employers are making available to their employees
The platform triages individual employees to the right level of care, providing clinical care to those with diagnosable depression or
anxiety, and making self-guided or preventative care available to everyone else
Their solution improves quality and access by offering mental health services to every employee and reduces the cost associated with
that leverage technology to impact cost, quality, and access
on the back of Pear and Akili, more companies push to FDA and enter the market
In addition, broader consumer platforms like Calm and Headspace look to broaden their offerings by investigating clinical approvals.At least
one major pharma looks to expand its consumer surface area by acquiring one of the new digital, consumer-facing generics platform (ex Hims,
neurodegeneration sees a renaissance
High-profile failings of Biogen and the beta-amyloid hypothesis sees a shift of innovation to early-stage biotech and venture creation.Big
pharma has its DeepMind moment acquiring at least one machine-learning (AI) enabled drug discovery company.Clinical trial tech investments
heat up; new companies and technologies emerge to make trials patients first and systems get smarter at finding the right patients at their
point of care; large incumbents like IQVIA, LabCorp and PPD get acquisitive.At least three traditional Sand Hill Road tech venture firms
open life science practices or raise dedicated funds.Machine learning targets chemistry driven by large advancements in transformer (NLP)
models; has the time for computational chemistry finally come?HCIT sees a renaissance driven by increased CIO responsibility towards data
Companies either working on federated ML to allow systems to speak to each other or lightweight edge applications enabling rapid clinical
deployment will see quick uptake and traction, until now impossible in HC.Kristin Baker Spohn, CRVIn the last 10 years, digital health has
deliver venture scale outcomes
